With $116 million in FY2025 product revenue and a $2.0 billion cash reserves, CRSP has separated itself from pre-commercial peers — but the path forward demands clear eyes on both opportunity and risk....
CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...
Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human...
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy ...
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today...
Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Editas Medicine...